表紙
市場調査レポート

インドの医薬品市場:調剤、原薬(API)、医薬品研究開発および製造受託サービス(CRAMS)、バイオシミラー、ジェネリック医薬品、ワクチン

PHARMACEUTICAL MARKET INDIA 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics & Vaccines

発行 Kelly Scientific Publications 商品コード 307690
出版日 ページ情報 英文 183 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
インドの医薬品市場:調剤、原薬(API)、医薬品研究開発および製造受託サービス(CRAMS)、バイオシミラー、ジェネリック医薬品、ワクチン PHARMACEUTICAL MARKET INDIA 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics & Vaccines
出版日: 2014年08月01日 ページ情報: 英文 183 Pages
概要

インドの医薬品市場は2015年までに世界第8位の市場となると予測されています。

当レポートでは、インドにおける医薬品およびバイオテクノロジー市場の現状と欧米や新興市場と比較したインドの現状、法規制動向とともに、主要参入企業の財務や製品動向などの包括的情報をまとめています。

第1章 サマリー

第2章 疫学および疾患概要

  • 心血管疾患
  • 感染症
  • 呼吸器感染
  • 結核
  • HIV
  • 肝炎
  • 腸チフス
  • デング熱
  • 糖尿病
  • 慢性呼吸疾患:喘息、COPD

第3章 第12次5か年計画

第4章 経済およびビジネス環境

  • 経済指標、貿易政策、商業貿易統計
  • インドのGDP、歴史および予測分析
  • 世界およびインドの経済見通し
  • 先進国と比較したインド経済見通し(米国、欧州)

第5章 インドの医薬品業界

  • 概要
  • インドの医薬品業界の発展
  • 医薬品輸出市場
  • 調製市場
  • 原薬市場
  • バイオシミラー市場
  • 医薬品研究開発・製造受託サービス(CRAMS)
  • インドの医薬品業界市場
  • 治療分野別市場シェア
  • インドのバイオテクノロジー市場
  • ジェネリック医薬品市場
  • ワクチン業界
  • 主要企業
  • 研究開発費の高騰
  • インドの医薬品業界における重要な市場動向

第6章 インドの製薬会社プロファイルと財務データ

  • Aurobindo Pharma
  • Bharat Serums and Vaccines Ltd
  • Biocon Biopharmaceuticals
  • Cipla
  • Divis Laboratories
  • Dr Reddy's Laboratories
  • Lupin
  • Mankind Pharma
  • Panacea Biotech
  • Piramal Group
  • Ranbaxy Laboratories
  • Reliance Life Sciences
  • Serum Institute of India
  • Sun Pharmaceuticals
  • Zydus Cadila

第7章 SWOT分析

第8章 企業ディレクトリと人材

第9章 付録

目次
Product Code: Q2014PMI

"PHARMACEUTICAL MARKET INDIA 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics & Vaccines" by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.

The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $x billion according to the India Brand Equity Foundation (IBEF). It is forecast to reach at least $x billion by 2020 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $x billion. This depends on the optimisation of the following submarkets: public health, generics, consumer healthcare drugs, biologics, vaccines and patented products.

This report describes the current therapeutics that are propelling the pharmaceutical and biotechnology markets in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. It is supported by 333 figures and tables over 183 pages and the reader has the opportunity to re-use and referene these exhibits in their own reports and presentations. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial and product review of key players in the pharmaceutical and biotechnology industry in India. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the Indian biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment.

Table of Contents

1.0 Summary

  • 1.1 Objectives of Report
  • 1.2 Scope of Study
  • 1.3 Data Sources and Methodology
  • 1.4 Key Findings and Observations
  • 1.5 Executive Summary

2.0 Epidemiology and Disease Overview

  • 2.1 Cardiovascular Disease
  • 2.2 Infectious Disease
  • 2.3 Respiratory Infections
  • 2.4 Tuberculosis
  • 2.5 HIV
  • 2.6 Hepatitis
  • 2.7 Typhoid Fever
  • 2.8 Dengue Fever
  • 2.9 Diabetes
  • 2.10 Cancer
  • 2.11 Chronic Respiratory Disease- Asthma and COPD

3.0 Twelfth Five Year Plan - A Boost for Scientific Research and Development

4.0 Economic and Business Environment

  • 4.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics
  • 4.2 Gross Domestic Product of India, Historic and Projection Analysis
  • 4.3 Global and India Economic Outlook 2010-2013
  • 4.4 Indian Economic Outlook in Comparison to Advanced Economies (US, Europe)

5.0 Indian Pharmaceutical Industry

  • 5.1 Overview
  • 5.2 Evolution of Indian Pharmaceutical Industry
  • 5.3 Pharmaceutical Export Market
  • 5.4 Formulations Market
  • 5.5 Active Pharmaceutical Ingredient Market
  • 5.6 Biosimilar Market
  • 5.7 Contract Research and Manufacturing Service (CRAMS)
  • 5.8 Indian Pharmaceutical Industry Market
  • 5.9 Evaluation of Market Share by Therapeutic Area
  • 5.10 Indian Biotechnology Industry
  • 5.11 Generic Drug Market
  • 5.12 Vaccine Industry in India
  • 5.13 Key Players
  • 5.14 R&D Spending on the Increase
  • 5.15 Important Market Trends Within the Indian Pharmaceutical Industry

6.0 Indian Pharmaceutical Company Profiles and Financial Data

  • 6.1 Aurobindo Pharma
  • 6.2 Bharat Serums and Vaccines Ltd
  • 6.3 Biocon Biopharmaceuticals
  • 6.4 Cipla
  • 6.5 Divis Laboratories
  • 6.6 Dr Reddy's Laboratories
  • 6.7 Lupin
  • 6.8 Mankind Pharma
  • 6.9 Panacea Biotech
  • 6.10 Piramal Group
  • 6.11 Ranbaxy Laboratories
  • 6.12 Reliance Life Sciences
  • 6.13 Serum Institute of India
  • 6.14 Sun Pharmaceuticals
  • 6.15 Zydus Cadila

7.0 SWOT Analysis of Indian Pharmaceutical Market

  • 7.1 Growth Factors
  • 7.2 Strengths of Indian Pharmaceutical Industry
  • 7.3 Main Weaknesses
  • 7.4 Significant Opportunities within the Indian Pharmaceutical Industry
  • 7.5 Threats and Considerations

8.0 Company Directory and Key People

  • 8.1 Aurobindo Pharma
  • 8.2 Bharat Serums and Vaccines Ltd
  • 8.3 Biocon Biopharmaceuticals
  • 8.4 Cipla
  • 8.5 Divis laboratories
  • 8.6 Dr Reddy's Laboratories
  • 8.7 Lupin
  • 8.8 Panacea Biotech
  • 8.9 Reliance Life Sciences

9.0 Appendix

  • 9.1 Comprehensive List of Pharmaceutical Company's in India
  • Exhibit 2.1: Key Statistics: India
  • Exhibit 2.2: National Expenditure on Health (Indian Rupee) 2000 - 2011
  • Exhibit 2.3: Top Ten Causes of Mortality in India 2008-2030
  • Exhibit 2.4: Estimated Number of Deaths Due to Most Prevalent Disease States, India
  • Exhibit 2.5: Historic and Projected Death Rates Due to Cardiovascular and Cancer, India 2004-2030
  • Exhibit 2.6: Trend of Communicable and Non-Communicable Disease Burden in Developing World
  • Exhibit 2.7: Cardiovascular Mortality by Indian State
  • Exhibit 2.8: Factors Contributing to High Prevalence of Cardiovascular Disease in India
  • Exhibit 2.9: Distribution of Cause of Death in Children under Five, India
  • Exhibit 2.10: Global Incidence of Childhood Clinical Pneumonia
  • Exhibit 2.11: Global Distribution of Deaths from Pneumonia and other Causes in Children
  • Exhibit 2.12: Revised National Tuberculosis Control Program (RNTCP) Statistics 2005-Present
  • Exhibit 2.13: Estimated Global Tuberculosis Incidence Rates
  • Exhibit 2.15: Estimated Global HIV Prevalence in New TB Cases
  • Exhibit 2.14: India TB Statistics by State, Population Covered, Diagnosis, Treatment Relapse and HIV Co-infection
  • Exhibit 2.16: Number of MDR-TB Cases Estimated to Occur Among Notified Pulmonary TB Cases 2011
  • Exhibit 2.17: Countries That Have Notified of at Least One XDR-TB Case
  • Exhibit 2.18: TB Vaccine Development Pipeline 2012
  • Exhibit 2.19: HIV Prevalence in India 2004-2009
  • Exhibit 2.20: Routes of HIV Transmission in India
  • Exhibit 2.21: Global Hepatitis E Virus Endemicity
  • Exhibit 2.22: Prevalence of Diabetes by Indian Region
  • Exhibit 2.23: Global Prevalence of Undiagnosed Diabetes
  • Exhibit 2.24: Incidence and Mortality Rates for Top Sixteen Cancers in India - Both Sexes
  • Exhibit 2.25: Prevalence of Cancer Cases and Deaths in India, Male and Female
  • Exhibit 2.26: Incidence and Mortality Rates for Top Sixteen Cancers in India - Men
  • Exhibit 2.27: Incidence and Mortality Rates for Top Sixteen Cancers in India - Women
  • Exhibit 2.28: Percentage Incidence Distribution of the most Frequent Cancers in India, Both Sexes
  • Exhibit 2.28: Percentage Mortality Distribution of the most Frequent Cancers in India, Both Sexes
  • Exhibit 2.29: Five Year Prevalence and Incidence of Top Twenty Cancer's in India
  • Exhibit 2.30: Mortality Rate (per 100,000) Attributable to Chronic Obstructive Pulmonary Disease Globally
  • Exhibit 3.1: India's Twelve Year Plan - Key Points in Relation to Science Research and Development
  • Exhibit 3.2: Budget for Specific Scientific Departments under India's Twelfth Five Year Plan
  • Exhibit 4.1: World Trade Organisation Basic Indicators on India
  • Exhibit 4.2: World Trade Organisation Trade Policy of India
  • Exhibit 4.3: World Trade Organisation Merchandise Trade Statistics: India
  • Exhibit 4.4: World Trade Organisation Commercial Services Trade Statistics: India
  • Exhibit 4.5: World Trade Organisation Industrial Property Statistics: India
  • Exhibit 4.6: India GDP Figures 2011-2018
  • Exhibit 4.7: India Health Expenditure as a Percentage of GDP 2000-2010
  • Exhibit 4.8: Global, Emerging Market & Developing Countries Economic Growth Change 2010-2013
  • Exhibit 4.9: Global, Emerging Market & Developing Countries & India Economic Growth Change 2010-2013
  • Exhibit 4.10: Global, Emerging Market, Developing Countries & Russia Economic Growth Change 2010-2013
  • Exhibit 4.11: Global, Emerging Market & Developing Countries & China Economic Growth Change 2010-2013
  • Exhibit 4.12: Global, Emerging Market & Developing Countries & Brazil Economic Growth Change 2010-2013
  • Exhibit 4.13: Global, US and Germany Economic Growth 2010-2013
  • Exhibit 4.14: US and UK Gross Domestic Product per capita Forecast 2010-2017
  • Exhibit 4.15: Global, France and Italy Economic Growth 2010-2013
  • Exhibit 4.16: France, Germany and Italy Gross Domestic Product per capita Forecast 2010-2017
  • Exhibit 4.17: Global, UK and Spain Economic Growth 2010-2013
  • Exhibit 4.18: Global, Japan and Canada Economic Growth 2010-2013
  • Exhibit 4.19: India, Brazil and China Gross Domestic Product per capita Forecast 2010-2017
  • Exhibit 5.1: Four Major Areas of the Indian Pharmaceutical Industry
  • Exhibit 5.2: Evolution Timeline of The Indian Pharmaceutical Industry
  • Exhibit 5.3: Indian Pharmaceutical Industry IPM and Exports 2003-2015
  • Exhibit 5.4: Indian Pharmaceutical Industry Bulk Drug Exports 2003-2015
  • Exhibit 5.5: Top 50 Exporting Pharmaceutical Companies in India
  • Exhibit 5.6: Indian Pharmaceutical Industry Formulation Exports 2003-2015
  • Exhibit 5.7: Indian Pharmaceutical Industry Domestic Formulations 2003-2015
  • Exhibit 5.8: Geographic Distribution of India's Active Pharmaceutical Ingredient Exports, 2012
  • Exhibit 5.9: Current Trends of the Global Biosimilar Market
  • Exhibit 5.10: Main Therapeutic Areas of the Future Biosimilar Market
  • Exhibit 5.11: Market Share ($ Billions) of Contract Manufacturing and Research within Indian CRAMS Industry
  • Exhibit 5.12: Market Share (Percentage) of Contract Manufacturing and Research within Indian CRAMS Industry
  • Exhibit 5.13: Indian Contract Research and Manufacturing Services (CRAMS) Market 2010-2015
  • Exhibit 5.14: Drivers and Resistors of the Indian CRAMS/CMO Industry
  • Exhibit 5.15: Advantages of Contract Research Organizations in India
  • Exhibit 5.16: Challenges of Contract Research Organizations in India
  • Exhibit 5.17: Areas of Growth and Potential for Indian Contract Research Organisation's
  • Exhibit 5.18: Indian Pharmaceutical Market Revenue 2005-2020
  • Exhibit 5.19: Generic Drug, Over the Counter and Patened Drug Sub-Market Revenue Share
  • Exhibit 5.20: India's Pharmaceutical Market Share by Value in the Asia-Pacific Region
  • Exhibit 5.21: Leading Players of the Indian Pharmaceutical Market
  • Exhibit 5.22: Top 20 Biotechnology Companies in India by Revenue FY2013
  • Exhibit 5.23: India - Significant Economic Indicators
  • Exhibit 5.24: Positive Factors Influencing the Indian Pharmaceutical Market
  • Exhibit 5.25: Quantitative Market Share of Acute and Chronic Therapy in India
  • Exhibit 5.26: Multinational Company Penetration into Indian Pharmaceutical Market
  • Exhibit 5.27: Key Factors Influencing Leading Player Position in India Pharma Market
  • Exhibit 5.28: Partnerships Between International Pharmaco's and Domestic API Partners
  • Exhibit 5.29: Indian Pharmaceutical Market Share (%) by Therapeutic Area 2013-Table Format
  • Exhibit 5.30: Indian Pharmaceutical Market Share (%) by Therapeutic Area 2013- Pie Chart Format
  • Exhibit 5.31: Indian Pharmaceutical Market Share (%) by Therapeutic Area
  • Exhibit 5.32: Top Five Fastest Growing Indian Pharma Market Segments
  • Exhibit 5.33: Top Biotechnology Companies by Revenue FY2013 (Barchart)
  • Exhibit 5.34: Top 20 Biotechnology Companies in India by Revenue FY2013 Table
  • Exhibit 5.35: Top Five Emerging Opportunities within the Indian Pharmaceutical Market
  • Exhibit 5.36: Top Five Indian Vaccine Manufacturers
  • Exhibit 5.37: Top Pharmaceutical Companies within the Indian Pharmaceutical Market by Market Share and Revenue
  • Exhibit 5.38: Percentage Market Share of Leading Players in the Indian Pharmaceutical Market
  • Exhibit 5.39: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2012
  • Exhibit 5.40: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2013
  • Exhibit 5.41: R&D Investment Comparison of Top Indian Pharmaco's 2010 Vs 2013
  • Exhibit 5.42: R&D Investment Table of Top Indian Pharmaco's 2010 Vs 2013
  • Exhibit 5.43: Investments, Acquisitions and Joint Ventures Between International and Indian Pharmacos
  • Exhibit 6.1: Aurobindo Pharma Therapeutic Areas of Interest
  • Exhibit 6.2: Aurobindo Pharma Formulation Unit Accreditation
  • Exhibit 6.3: Aurobindo Pharma Range of Anti-Infective Formulations
  • Exhibit 6.4: Aurobindo Pharma Therapeutic Areas of Interest
  • Exhibit 6.5: Aurobindo Pharma Antiretroviral Therapeutic Product Portfolio
  • Exhibit 6.6: Aurobindo Pharma Antiosteoporotic Therapeutic Product Portfolio
  • Exhibit 6.7: Aurobindo Pharma Antihypertensive Therapeutic Product Portfolio
  • Exhibit 6.8: Aurobindo Pharma Antiasthmatic Therapeutic Product Portfolio
  • Exhibit 6.9: Aurobindo Pharma Beta-Lactam-Antibiotic Product Portfolio
  • Exhibit 6.10: Aurobindo Pharma Anti Erectile Dysfunction Product Portfolio
  • Exhibit 6.11: Aurobindo Pharma Antiosteoporotic Product Portfolio
  • Exhibit 6.12: Aurobindo Pharma Alzheimer's Product Portfolio
  • Exhibit 6.13: Aurobindo Pharma Antibiotic Product Portfolio
  • Exhibit 6.14: Aurobindo Pharma Antidepressant Product Portfolio
  • Exhibit 6.15: Aurobindo Pharma Antidiabetic Product Portfolio
  • Exhibit 6.16: Aurobindo Pharma Antiemetic Product Portfolio
  • Exhibit 6.17: Aurobindo Pharma Antiepileptic Therapeutic Portfolio
  • Exhibit 6.18: Aurobindo Pharma Cardiovascular Therapeutic Portfolio
  • Exhibit 6.19: Aurobindo Pharma CNS Therapeutic Portfolio
  • Exhibit 6.20: Aurobindo Pharma Pain Management Therapeutic Portfolio
  • Exhibit 6.21: Aurobindo Pharma Consolidated Revenue FY2010-FY2013
  • Exhibit 6.22: Aurobindo Pharma Revenue Breakdown: Formulation and API Sales FY2013
  • Exhibit 6.23: Aurobindo Pharma Subsidiary Companies
  • Exhibit 6.24: Aurobindo Pharma Long Term Growth Strategies
  • Exhibit 6.25: Bharat Serums and Vaccines Significant Milestones
  • Exhibit 6.26: Bharat Serums and Vaccines Range of Products
  • Exhibit 6.27: Bharat Serums and Vaccines Plasma Serum Product Portfolio
  • Exhibit 6.28: Bharat Serums and Vaccines Monoclonal Antibody Product Portfolio
  • Exhibit 6.29: Bharat Serums and Vaccines Equine Antitoxin and Serum Product Portfolio
  • Exhibit 6.30: Bharat Serums and Vaccines Cardiovascular Product Portfolio
  • Exhibit 6.31: Bharat Serums and Vaccines Anti-microbial Product Portfolio
  • Exhibit 6.32: Bharat Serums and Vaccines Anti-fungal Product Portfolio
  • Exhibit 6.33: Bharat Serums and Vaccines Anaesthesia Product Portfolio
  • Exhibit 6.34: Bharat Serums and Vaccines Hormone Product Portfolio
  • Exhibit 6.35: Biocon Biopharmaceuticals Business Outline
  • Exhibit 6.36: Biocon Biopharmaceuticals Five Key Business Areas
  • Exhibit 6.37: Biocon Biopharmaceuticals Subsidiary Companies
  • Exhibit 6.38: Biocon Biopharmaceuticals Important Milestones
  • Exhibit 6.39: Biocon Biopharmaceuticals Active Pharmaceutical Ingredients (APIs) Product Areas
  • Exhibit 6.40: Biocon Biopharmaceuticals Active Biological Product Areas
  • Exhibit 6.41: Biocon Biopharmaceuticals Diabetes Branded Formulations
  • Exhibit 6.42: Biocon Biopharmaceuticals Oncology Branded Therapeutics
  • Exhibit 6.43: Biocon Biopharmaceuticals Nephrology Branded Therapeutics
  • Exhibit 6.44: Biocon Biopharmaceuticals Cardiology Branded Therapeutics
  • Exhibit 6.45: Biocon Biopharmaceuticals Comprehensive Care Branded Therapeutics
  • Exhibit 6.46: Biocon Biopharmaceuticals Immunotherapy Branded Therapeutics
  • Exhibit 6.47: Biocon Biopharmaceuticals BioTherapy Branded Therapeutics
  • Exhibit 6.48: Biocon Biopharmaceuticals - Syngene Service Platform
  • Exhibit 6.49: Biocon Biopharmaceuticals - Clinigene Service Platform
  • Exhibit 6.50: Biocon Biopharmaceuticals Revenue 2008-2014
  • Exhibit 6.51: Biocon Biopharmaceuticals Revenue 2008-2014
  • Exhibit 6.52: Biocon Biopharmaceuticals Profits from Operations 2008-2014
  • Exhibit 6.53: Biocon Biopharmaceuticals Profits from Operations 2008-2014
  • Exhibit 6.54: Cipla Important Milestones
  • Exhibit 6.55: Cipla Main Therapeutics Areas of Interest
  • Exhibit 6.56: Cipla Export Market Share FY2012-2013
  • Exhibit 6.57: Cipla Sales and Other Income Exhibits 2003-2013
  • Exhibit 6.58: Cipla Profit after Tax Figures 2003-2013
  • Exhibit 6.59: Cipla Significant Product Launches
  • Exhibit 6.60: Cipla Significant Active Pharmaceutical Ingredient Commercialisation Launches
  • Exhibit 6.61: Divis Laboratories Important Milestones
  • Exhibit 6.62: Divis Laboratories Product Category Portfolio
  • Exhibit 6.63: Divis Laboratories Product List
  • Exhibit 6.64: Divis Laboratories Income From Operations 2006-2013
  • Exhibit 6.65: Divis Laboratories Future Pipeline Portfolio
  • Exhibit 6.66: Dr Reddy's Therapeutic Areas of Interest
  • Exhibit 6.67: Dr Reddy's Laboratories - Important Milestones
  • Exhibit 6.68: Dr Reddy's Labs Top Active Pharmaceutical Ingredients
  • Exhibit 6.69: Dr Reddy's Labs Top Brands in India
  • Exhibit 6.70: Dr Reddy's Laboratories Annual Revenue Figures 2003-2014
  • Exhibit 6.71: Dr Reddy's Laboratories Historical Revenue Figures 2006-2014 (Global)
  • Exhibit 6.72: Dr Reddy's Laboratories Geographical Revenue Percentage
  • Exhibit 6.73: Dr Reddy's Key Brand Revenue in Russia 2011-2012
  • Exhibit 6.74: Dr Reddy's Key Brand Revenue in India 2011-2012
  • Exhibit 6.75: Dr Reddy's Therapeutic Agents and Classes undergoing Clinical Trials
  • Exhibit 6.76: Lupin Significant Milestones
  • Exhibit 6.77: Lupin Ltd Formulations Product Portfolio
  • Exhibit 6.78: Lupin Ltd Active Pharmaceutical Ingredient Product Portfolio
  • Exhibit 6.79: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Business Contribution
  • Exhibit 6.80: Lupin Ltd Formulations and Active Pharmaceutical Ingredient Exports 2006-2012
  • Exhibit 6.81: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Revenue Contribution
  • Exhibit 6.82: Lupin Ltd Geographic Breakdown of Revenue
  • Exhibit 6.83: Lupin Ltd Net Global Sales 2008-2014
  • Exhibit 6.84: Lupin Ltd Profit Before Tax 2008-2013
  • Exhibit 6.85: Lupin Ltd Formulation Sales 2006-2013 Indian Market
  • Exhibit 6.86: Lupin Ltd Top Product Brands in the Indian Market and Ranking
  • Exhibit 6.87: Lupin Ltd Therapeutic Area Growth Increase in Comparison to Overall Market Growth
  • Exhibit 6.88: Lupin Pharma Key Products and Rank in the Indian Market
  • Exhibit 6.89: Lupin Respira Key Products and Rank in the Indian Market
  • Exhibit 6.90: Lupin Endeavour Key Products and Rank in the Indian Market
  • Exhibit 6.91: Lupin Maxter Key Products and Rank in the Indian Market
  • Exhibit 6.92: Lupin Pinnacle CVS Key Products and Rank in the Indian Market
  • Exhibit 6.93: Lupin Diabetes Care Key Products and Rank in the Indian Market
  • Exhibit 6.94: Lupin Mindvision Key Products and Rank in the Indian Market
  • Exhibit 6.95: Lupin Ikonic Key Products and Rank in the Indian Market
  • Exhibit 6.96: Lupin Pharmaceuticals Formulation Sales US Market 2007-2013
  • Exhibit 6.97: Lupin Ltd Performance in Top Five Generic Pharmaceutical Companies in the US Market
  • Exhibit 6.98: Lupin Ltd Percentage Market Share within US Generics Market
  • Exhibit 6.99: Lupin Ltd (Kyowa Pharmaceutical) Sales in Japanese Market 2008-2014
  • Exhibit 6.100: Lupin Ltd Division of Sales by Therapeutic Area
  • Exhibit 6.101: Lupin Ltd Advanced Drug Delivery System Platform Portfolio
  • Exhibit 6.102: Lupin Ltd Research and Development Areas of Expertise
  • Exhibit 6.103: Mankind Pharma Company Divisions
  • Exhibit 6.104: Mankind Pharma Key Milestones
  • Exhibit 6.105: Mankind Pharma Therapeutic Areas of Interest
  • Exhibit 6.106: Mankind Pharma Prescription Product Areas
  • Exhibit 6.107: Mankind Pharma Top Ten Brands
  • Exhibit 6.108: Mankind Pharma Diabetic Product Brands
  • Exhibit 6.109: Mankind Pharma Hyperthyroidism Product Brands
  • Exhibit 6.110: Mankind Pharma Cough Product Brands
  • Exhibit 6.111: Mankind Pharma Malaria Product Brands
  • Exhibit 6.112: Mankind Pharma Migraine Product Brands
  • Exhibit 6.113: Mankind Pharma Anti-viral Product Brands
  • Exhibit 6.114: Mankind Pharma Steroid Product Brands
  • Exhibit 6.115: Mankind Pharma Dermatology Product Brands
  • Exhibit 6.116: Mankind Pharma Ophthalmology Product Brands
  • Exhibit 6.117: Mankind Pharma Gynaecology Product Brands
  • Exhibit 6.118: Mankind Pharma Antibiotic Product Brands
  • Exhibit 6.119: Mankind Pharma Asthmatic Product Brands
  • Exhibit 6.120: Panacea Biotech Strategic Business Unit Structure
  • Exhibit 6.121: Panacea Biotech Therapeutic Areas of Interest
  • Exhibit 6.122: Panacea Biotech Leading Brands in India
  • Exhibit 6.123: Panacea Biotech Pain Management Therapy Portfolio
  • Exhibit 6.124: Panacea Biotech Diacar Alpha and Diacar Delta SBU Oral Hypoglycaemic Product Range
  • Exhibit 6.125: Panacea Biotech Diacar Alpha and Diacar Delta SBU Cardiovascular Product Range
  • Exhibit 6.126: Panacea Biotech Vaccine Portfolio
  • Exhibit 6.127: Panacea Biotech Diabetes Management Portfolio
  • Exhibit 6.128: Panacea Biotech Anti-Osteoporotic Portfolio
  • Exhibit 6.129: Panacea Biotech Antipyretic, Anti-inflammatory and Analgesic Portfolio
  • Exhibit 6.130: Panacea Biotech Renal Disease Management Portfolio
  • Exhibit 6.131: Panacea Biotech Gastro Intestinal Product Portfolio
  • Exhibit 6.132: Panacea Biotech Constipation Product Portfolio
  • Exhibit 6.133: Panacea Biotech Tuberculosis Product Portfolio
  • Exhibit 6.134: Panacea Biotech Cough/Cold Product Portfolio
  • Exhibit 6.135: Panacea Biotech Brand Standing and Market Share (India) - Diabetes and Cardiac Care
  • Exhibit 6.136: Panacea Biotech Brand Standing and Market Share (India) - Pain Management
  • Exhibit 6.137: Panacea Biotech Brand Standing and Market Share (India) - Tuberculosis Treatment
  • Exhibit 6.138: Panacea Biotech Brand Standing and Market Share (India) - Gastrointestinal Treatment
  • Exhibit 6.139: Panacea Biotech Brand Standing and Market Share (India) - Anti-Haemorrhoidal
  • Exhibit 6.140: Panacea Biotech Brand Standing and Market Share (India) - Penicillins
  • Exhibit 6.141: Panacea Biotech Current Patents for Licencing
  • Exhibit 6.142: Panacea Biotech Net Turnover 2002-2013
  • Exhibit 6.143: Panacea Biotech Net Turnover 2002-2013
  • Exhibit 6.144: Panacea Biotech Geographic Distribution of Sales, 2010-2012
  • Exhibit 6.145: Panacea Biotech Geographic Distribution of Sales, 2010-2012
  • Exhibit 6.146: Key Milestones in Piramal Group History
  • Exhibit 6.147: Piramal Distribution of Sales (Percentage) 2014
  • Exhibit 6.148: Piramal Distribution of Pharma Solutions Domestic and International Sales (Percentage)
  • Exhibit 6.149: Piramal Pharma Solutions Sales (Rs Crores) from Domestic and International Assets
  • Exhibit 6.150: Piramal Oncology Therapeutic Pipeline
  • Exhibit 6.151: Piramal Inflammation Therapeutic Pipeline
  • Exhibit 6.152: Piramal Diabetic and Metabolic Disease Therapeutic Pipeline
  • Exhibit 6.153: Piramal Infectious Disease Therapeutic Pipeline
  • Exhibit 6.154: Ranbaxy Laboratories - Therapeutic Markets of Interest
  • Exhibit 6.155: Ranbaxy's Oral Platform Technologies using a Novel Drug Delivery System
  • Exhibit 6.156: Ranbaxy Laboratories - Top Ten Therapeutics
  • Exhibit 6.157: Ranbaxy Key Merger and Acquisition Activity
  • Exhibit 6.158: List of Ranbaxy Subsidiary Companies
  • Exhibit 6.159: Ranbaxy - Future Therapeutic Areas
  • Exhibit 6.160: Ranbaxy Global Sales by Geographical Region FY2014
  • Exhibit 6.161: Ranbaxy Developed and Emerging Market Share FY2014
  • Exhibit 6.162: Ranbaxy Sales Figures, USA and Canada, FY2014
  • Exhibit 6.163: Ranbaxy Sales Figures, Western Europe FY2014
  • Exhibit 6.164: Ranbaxy Sales Figures, East Europe and CIS FY2014
  • Exhibit 6.165: Ranbaxy Top Sellers in India
  • Exhibit 6.166: Ranbaxy Sales Figures, India, 2010-2014
  • Exhibit 6.167: Ranbaxy Market Share of Top Therapeutics, India
  • Exhibit 6.168: Ranbaxy Launches by Geographical Region
  • Exhibit 6.169: Reliance Life Sciences Biopharmaceutical Product Areas
  • Exhibit 6.170: Reliance Life Sciences Pharmaceutical Product Areas
  • Exhibit 6.171: Reliance Life Sciences Clinical Research Services
  • Exhibit 6.172: Reliance Life Sciences Regenerative Medicine Product Areas
  • Exhibit 6.173: Reliance Life Sciences Molecular Medicine Product Areas
  • Exhibit 6.174: Reliance Life Science Plasma Protein Product Portfolio
  • Exhibit 6.175: Reliance Life Science Biosimilar Product Portfolio
  • Exhibit 6.176: Reliance Life Science Pharmaceutical Product Portfolio
  • Exhibit 6.177: Reliance Life Science Regenerative Medicine Product Portfolio
  • Exhibit 6.178: Reliance Life Science R&D Activities
  • Exhibit 6.179: Serum Institute of India Significant Milestones
  • Exhibit 6.180: Serum Institute of India Revenue FY2011-2013
  • Exhibit 6.181: Serum Institute of India Manufactured Products
  • Exhibit 6.182: Serum Institute of India Marketed Products
  • Exhibit 6.183: Serum Institute of India Exported Products
  • Exhibit 6.184: Serum Institute of India Product Pipeline
  • Exhibit 6.185: Sun Pharmaceuticals Revenue Stream by Formulation, Generics and API's 2013-2014
  • Exhibit 6.186: Sun Pharmaceuticals Revenue Stream by Formulation, Generics and API's 2011-2012
  • Exhibit 6.187: Sun Pharmaceuticals - Important Milestones
  • Exhibit 6.188: Sun Pharmaceutical Revenue Stream 2011-2012 ($ Millions)
  • Exhibit 6.189: Sun Pharmaceuticals Percentage Breakdown of Therapeutic Area Sales 2013-2014
  • Exhibit 6.190: Sun Pharmaceuticals Percentage Breakdown of Therapeutic Area Sales 2012-2013
  • Exhibit 6.191: Sun Pharmaceuticals Top Ten Branded Generics in India
  • Exhibit 6.192: Sun Pharmaceuticals Number of Drug Approvals by Therapeutic Area
  • Exhibit 6.193: Zydus Research Centre Speciality Areas of Research
  • Exhibit 6.194: Zydus Cadila Vaccine R&D Areas of Research
  • Exhibit 6.195: Zydus Cadila Global 'Beyond the Billion' Business Development Strategy
  • Exhibit 6.196: Zydus Cadila Top Formulation Brands in the Indian Market
  • Exhibit 6.197: Zydus Cadila New Molecular Entities in Development Pipeline
  • Exhibit 6.198: Zydus Cadila Biosimilar Therapeutics in Development Pipeline
  • Exhibit 6.199: Zydus Cadila Indian Formulation Market Distribution (%) by Therapeutic Area 2014
  • Exhibit 6.200: Zydus Cadila Gross Sales FY2012-FY2014
  • Exhibit 6.201: Zydus Cadila List of Subsidiary Companies
  • Exhibit 6.202: Zydus Cadila Key Acquisitions 1995-2012
  • Exhibit 6.203: Zydus Cadila Research and Development Areas of Interest
  • Exhibit 7.1: Main Growth Factors of the Indian Pharmaceutical Market
  • Exhibit 7.2: Indian Health Insurance Coverage Statistics 2010-2020
  • Exhibit 7.3: Demand Drivers of the Indian Pharmaceutical Industry
  • Exhibit 7.4: Strengths of the Indian Pharmaceutical Market
  • Exhibit 7.5: Weaknesses of the Indian Pharmaceutical Market
  • Exhibit 7.6: Opportunities within the Indian Pharmaceutical Market
  • Exhibit 7.7: Threats to the Indian Pharmaceutical Market
  • Exhibit 8.1: Aurobindo Pharma Key Contact Details
  • Exhibit 8.2: Aurobindo Pharma Board of Directors and Key Personnel
  • Exhibit 8.3: Bharat Serums and Vaccines Ltd General Contact Details
  • Exhibit 8.4: Bharat Serums and Vaccines Ltd Board of Directors
  • Exhibit 8.5: Biocon Biopharmaceuticals Key Contact Details
  • Exhibit 8.6: Biocon Biopharmaceuticals Board of Directors
  • Exhibit 8.7: Biocon Biopharmaceuticals Key Management Team
  • Exhibit 8.8: Cipla Executive Directors
  • Exhibit 8.9: Cipla Non-Executive/Independent Directors
  • Exhibit 8.10: Cipla Corporate Contact Details
  • Exhibit 8.11: Divis Laboratories Key Contact Details
  • Exhibit 8.12: Divis Laboratories Key People
  • Exhibit 8.13: Dr Reddy's Laboratories Contact Information
  • Exhibit 8.14: Dr Reddy's Laboratories Key People
  • Exhibit 8.15: Dr Reddy's Laboratories Board of Directors
  • Exhibit 8.16: Dr Reddy's Audit Committee Members
  • Exhibit 8.17: Dr Reddy's Nomination, Governance & Compensation Committee Members
  • Exhibit 8.18: Dr Reddy's Risk Management Committee Members
  • Exhibit 8.19: Dr Reddy's Science, Technology and Operations Committee Members
  • Exhibit 8.20: Dr Reddy's Shareholders' Grievance Committee Members
  • Exhibit 8.21: Dr Reddy's Investment Committee Members
  • Exhibit 8.22: Dr Reddy's Management Committee Members
  • Exhibit 8.23: Lupin Board of Directors
  • Exhibit 8.24: Lupin Key Management Players
  • Exhibit 8.25: Lupin Ltd General Contact Details
  • Exhibit 8.26: Panacea Biotech - Whole Time Directors
  • Exhibit 8.27: Panacea Biotech - Independent Directors
  • Exhibit 8.28: Panacea Biotech - Investor Contact Details
  • Exhibit 8.29: Panacea Biotech - General Contact Details
  • Exhibit 8.30: Reliance Life Sciences - General Contact Details
Back to Top